News InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
1.26 ^USD	-0.40%		-18.18%	-22.70%

Mar. 21	Transcript : InflaRx N.V. - Special Call
Mar. 21	InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : InflaRx N.V. - Special Call	Mar. 21
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
InflaRx N : News Conference Call March 2024	Mar. 21	PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	Mar. 21	AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	Mar. 19	AQ
InflaRx Appoints Jan Medina as Head of Investor Relations	Feb. 22	AQ
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations	Feb. 22	CI
HC Wainwright Adjusts Price Target on InflaRx to $8 From $9, Keeps Buy Rating	Jan. 25	MT
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	Jan. 25	GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904	Jan. 04	CI
Transcript : InflaRx N.V. - Special Call	Jan. 04
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	Jan. 04	AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	Nov. 06	AQ
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	Nov. 06	CI
Top Premarket Gainers	Nov. 03	MT
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 01	PU
INFLARX N : UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 - Form 6-K	Nov. 01	PU
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 01	AQ
Top Premarket Gainers	23-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News InflaRx N.V.

Equities

IFRX

NL0012661870

Summary

Filters